SRPT stock sentiment todaySarepta Therapeutics, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
SRPT
Sarepta Therapeutics, Inc.The FDA's recent expansion of Elevidys to nearly all Duchenne Muscular Dystrophy patients transforms SRPT from a niche player into a commercial powerhouse.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for SRPT. Not financial advice.
Price · last 12 months
Gossip
The narrative is dominated by the 'label expansion' victory for Elevidys, which removed age and ambulatory restrictions, effectively tripling the addressable market. While the stock experiences volatility based on reimbursement rollouts, the sentiment is overwhelmingly focused on its path to becoming a mid-cap biotech leader.
- ·FDA full approval for Elevidys
- ·Massive expansion of the patient population (label expansion)
- ·High short interest covering potential
- ·Speculation on acquisition by Big Pharma (e.g., Roche)
Financial
SRPT is transitioning from a high-burn R&D firm to a high-margin commercial entity. Revenue growth is accelerating sharply, and the company is nearing sustainable GAAP profitability as Elevidys sales scale globally.
- ·Revenue growth exceeding 90% year-over-year in recent quarters
- ·Cash position over $1.4 billion providing significant runway
- ·Elevidys price point of $3.2M creates massive revenue per patient
- ·Negative trailing P/E shifting toward positive forward outlook
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Insurance reimbursement hurdles for multi-million dollar therapies
- ·Regulatory scrutiny on long-term efficacy data
- ·Pipeline concentration in gene therapy which faces manufacturing complexities
Peer temperature
How direct competitors stack up against SRPT right now.
- NEUTRALBMRNBioMarin Pharmaceutical
COLDER — slower growth profile and struggling with the launch of its own gene therapy (Roctavian) compared to SRPT's rapid adoption.
See full analysis → - HOTVRTXVertex Pharmaceuticals
HOTTER — offers a more diversified portfolio and massive cash flow from cystic fibrosis, though with less immediate 'explosive' upside than SRPT.
See full analysis → - COLDPTCTPTC Therapeutics
COLDER — facing significant regulatory setbacks and a less competitive product profile in the Duchenne muscular dystrophy space.
See full analysis →
- SRPT+2.2%
- BMRN-2.5%
- VRTX+6.9%
- PTCT-7.4%
Analyst price target
Consensus average of 16 analysts · median 20.00
Source: StockAnalysis.com · updated 2026-10-30
AI-generated analysis for informational purposes only. Not financial advice.